Guanglin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guanglin Xu has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Cheng Cheng
Nanjing Drum Tower Hospital Institute for Life and Health, College of Life Sciences, Nanjing Normal University, Nanjing 210046, China
4 shared publicationsJinling Xu
College of Life Science, Nanjing Normal University, Nanjing, China
4 shared publicationsSai Li
Nanjing Drum Tower Hospital Institute for Life and Health, College of Life Sciences, Nanjing Normal University, Nanjing 210046, China
4 shared publicationsTing Wu
Nanjing Drum Tower Hospital Institute for Life and Health, College of Life Sciences, Nanjing Normal University, Nanjing 210046, China
4 shared publicationsWeijie Li
College of Life Science, Nanjing Normal University, Nanjing, China
4 shared publicationsXinyu Fu
Nanjing Drum Tower Hospital Institute for Life and Health, College of Life Sciences, Nanjing Normal University, Nanjing 210046, China
4 shared publications
Latest Publications
- 15 June 2026
- Published by Wiley in ChemBioChem
- Vol. 27 (11) , e70416
Harnessing the Versatility of SAM‐Dependent Enzymes: From Mechanism to Application
S‐Adenosyl‐ L ‐methionine (SAM) is a central biological cofactor that supplied activated methyl groups and enables a broad‐spectrum biochemical transformation. Beyond canonical S N 2 methyl transfer, SAM‐dependent enzymes could initiate radical‐mediated chemistry via reductive SAM cleavage, enabling versatile reactions from methyl transfer to alkylation, isomerization, and decarboxylation. Despite their extraordinary catalytic plasticity and potential for sustainable industrial synthesis, SAM‐dependent enzymes are often limited by insufficient activity, stability, and substrate scope, necessitating further engineering. In this review, we summarize SAM‐dependent enzymes into methylation and nonmethylation catalytic systems, and systematically summarize recent protein engineering efforts aimed at enhancing activity, selectivity, and stability. Together, these advances establish a unified framework for unlocking the full catalytic potential of SAM‐dependent enzymes, paving the way for their integration as versatile and sustainable biocatalysts in modern chemical synthesis.
- 15 June 2026
- Published by Wiley in ChemBioChem
- Vol. 27 (11) , e70416
Harnessing the Versatility of SAM‐Dependent Enzymes: From Mechanism to Application
S‐Adenosyl‐ L ‐methionine (SAM) is a central biological cofactor that supplied activated methyl groups and enables a broad‐spectrum biochemical transformation. Beyond canonical S N 2 methyl transfer, SAM‐dependent enzymes could initiate radical‐mediated chemistry via reductive SAM cleavage, enabling versatile reactions from methyl transfer to alkylation, isomerization, and decarboxylation. Despite their extraordinary catalytic plasticity and potential for sustainable industrial synthesis, SAM‐dependent enzymes are often limited by insufficient activity, stability, and substrate scope, necessitating further engineering. In this review, we summarize SAM‐dependent enzymes into methylation and nonmethylation catalytic systems, and systematically summarize recent protein engineering efforts aimed at enhancing activity, selectivity, and stability. Together, these advances establish a unified framework for unlocking the full catalytic potential of SAM‐dependent enzymes, paving the way for their integration as versatile and sustainable biocatalysts in modern chemical synthesis.
- 21 April 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1870 (7) , 130956
SSD: Targeting inflammasome and oxidative stress as a therapeutic strategy in inflammatory diseases
- 21 April 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1870 (7) , 130956
SSD: Targeting inflammasome and oxidative stress as a therapeutic strategy in inflammatory diseases
- 3 February 2026
- Published by Elsevier in Molecular Pharmacology
- Vol. 108 (3) , 100105
Cepharanthine, a valuable sanative alternative for hepatocellular carcinoma through regulating Hippo-Yes-associated protein signal transduction
- 3 February 2026
- Published by Elsevier in Molecular Pharmacology
- Vol. 108 (3) , 100105
Cepharanthine, a valuable sanative alternative for hepatocellular carcinoma through regulating Hippo-Yes-associated protein signal transduction
- 5 December 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 169, 115934
DXFD-1 alleviates DSS-induced ulcerative colitis by targeting NF-κB and Nrf2 signaling
- 5 December 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 169, 115934
DXFD-1 alleviates DSS-induced ulcerative colitis by targeting NF-κB and Nrf2 signaling
- Open Access
- 30 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
M464 inhibits activation of NLRP3 inflammasome and inflammatory response in mice
Non-steroidal anti-inflammatory drugs (NSAIDs) function as antipyretic, analgesic and anti-inflammatory agents. However, its long application might result in gastrointestinal side effects. Therefore, it is imperative to hunt for novel and safer NSAIDs. Here, we report a new class of NSAIDs, M464, which was equipped with a hydrogen sulfide-releasing radical. We delved into its anti-inflammatory properties and underlying molecular mechanisms. In vitro, the relevance of the anti-inflammatory effects of M464 through the NLRP3 signaling pathway was explored by lactate dehydrogenase (LDH) release, WB (Western Blotting), ELISA assays and immunofluorescence experiments. In vivo, the influence and correlation of M464 on liver and lung tissue injury were investigated by means of histological evaluation, pathological analysis and serum index analysis. The correlation between M464 and NLRP3 signaling pathway in vivo injury model and its mechanism were investigated by Western Blotting and qPCR. In vitro results showed that M464 inactivates the assembly of the NLRP3 inflammasome, reduces the cleavage of Caspase-1 and the production of mature IL-1β, alleviates the generation of intracellular ROS, and decreases the oligomerization of the apoptosis-associated speck-like protein containing a CARD (ASC). In vivo results showed that M464 can down-regulate gene and protein expression levels of IL-1β and Caspase-1 in mice liver and lung injury models. M464 exhibits protective effects against acute lung and liver injury in mice, suggesting that M464 may be an alternative strategy to treat diseases driven by NLRP3 inflammasome activation.
- 30 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessM464 inhibits activation of NLRP3 inflammasome and inflammatory response in mice
Non-steroidal anti-inflammatory drugs (NSAIDs) function as antipyretic, analgesic and anti-inflammatory agents. However, its long application might result in gastrointestinal side effects. Therefore, it is imperative to hunt for novel and safer NSAIDs. Here, we report a new class of NSAIDs, M464, which was equipped with a hydrogen sulfide-releasing radical. We delved into its anti-inflammatory properties and underlying molecular mechanisms. In vitro, the relevance of the anti-inflammatory effects of M464 through the NLRP3 signaling pathway was explored by lactate dehydrogenase (LDH) release, WB (Western Blotting), ELISA assays and immunofluorescence experiments. In vivo, the influence and correlation of M464 on liver and lung tissue injury were investigated by means of histological evaluation, pathological analysis and serum index analysis. The correlation between M464 and NLRP3 signaling pathway in vivo injury model and its mechanism were investigated by Western Blotting and qPCR. In vitro results showed that M464 inactivates the assembly of the NLRP3 inflammasome, reduces the cleavage of Caspase-1 and the production of mature IL-1β, alleviates the generation of intracellular ROS, and decreases the oligomerization of the apoptosis-associated speck-like protein containing a CARD (ASC). In vivo results showed that M464 can down-regulate gene and protein expression levels of IL-1β and Caspase-1 in mice liver and lung injury models. M464 exhibits protective effects against acute lung and liver injury in mice, suggesting that M464 may be an alternative strategy to treat diseases driven by NLRP3 inflammasome activation.
- 15 January 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 132 (4) , 297-311
Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway
Hepatocellular carcinoma (HCC) is one of the principle causes of cancer‐associated death throughout the world. However, the patients with HCC are insensitive to traditional drugs and lack effective therapeutic drugs. Dysregulation of Hippo‐Yes‐associated protein (YAP) signalling is closely associated with HCC. Bortezomib (BTZ) is mainly used in clinical multiple myeloma. It has recently been confirmed that BTZ could suppress cell proliferation in many different types of cancer. Nevertheless, the precise effects of BTZ on HCC and its possible interactions with the Hippo‐YAP signalling pathway in HCC cells remain largely unknown. In this study, HCC cell lines (HepG2 and Huh7) and nude mice with xenograft tumours were used to evaluate the influences of BTZ. Furthermore, we focused on exploring whether BTZ exerts its anti‐HCC effect through the Hippo‐YAP signalling pathway and aimed to lay a theoretical foundation for BTZ as a potential therapeutic drug for HCC. Herein, our results disclose a new mechanism of BTZ in controlling the cell growth of HCC. BTZ downregulates the level of YAP by promoting LATS1 expression to inhibit the growth of HCC cells, which leads to the phosphorylation of YAP and limits YAP nuclear translocation. In sum, our data confirmed that the Hippo‐YAP signalling pathway mediates the anti‐HCC effects of BTZ.
- 15 January 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 132 (4) , 297-311
Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway
Hepatocellular carcinoma (HCC) is one of the principle causes of cancer‐associated death throughout the world. However, the patients with HCC are insensitive to traditional drugs and lack effective therapeutic drugs. Dysregulation of Hippo‐Yes‐associated protein (YAP) signalling is closely associated with HCC. Bortezomib (BTZ) is mainly used in clinical multiple myeloma. It has recently been confirmed that BTZ could suppress cell proliferation in many different types of cancer. Nevertheless, the precise effects of BTZ on HCC and its possible interactions with the Hippo‐YAP signalling pathway in HCC cells remain largely unknown. In this study, HCC cell lines (HepG2 and Huh7) and nude mice with xenograft tumours were used to evaluate the influences of BTZ. Furthermore, we focused on exploring whether BTZ exerts its anti‐HCC effect through the Hippo‐YAP signalling pathway and aimed to lay a theoretical foundation for BTZ as a potential therapeutic drug for HCC. Herein, our results disclose a new mechanism of BTZ in controlling the cell growth of HCC. BTZ downregulates the level of YAP by promoting LATS1 expression to inhibit the growth of HCC cells, which leads to the phosphorylation of YAP and limits YAP nuclear translocation. In sum, our data confirmed that the Hippo‐YAP signalling pathway mediates the anti‐HCC effects of BTZ.
- 11 September 2022
- Published by Elsevier in European Journal of Pharmacology
- Vol. 933, 175261
M378 exhibits anti-inflammatory activities through NLRP3 signaling pathway
- 11 September 2022
- Published by Elsevier in European Journal of Pharmacology
- Vol. 933, 175261
M378 exhibits anti-inflammatory activities through NLRP3 signaling pathway
- 1 January 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 842, 281-290
Molecular evidence for better efficacy of hypocrellin A and oleanolic acid combination in suppression of HCC growth
- 1 January 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 842, 281-290
Molecular evidence for better efficacy of hypocrellin A and oleanolic acid combination in suppression of HCC growth
- Open Access
- 16 October 2017
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 36 (1) , 1-20
YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer
Chemotherapy resistance remains a major challenge in cancer treatment. COX-2 (cyclooxygenase 2) is involved in drug resistance and poor prognosis of many neoplastic diseases or cancers. However, investigations identifying new modulators of COX-2 pathway and searching for new chemicals targeting these valid resistant biomarkers are still greatly needed. HCT15, HCT-116, HT-29, COLO205, FHC, IMCE, SW480 cell lines were used to detect the expression of YAP and COX-2. Site-directed mutagenesis, luciferase reporter analysis and ChIP assay were used to test whether YAP activated COX-2 transcription through interaction with TEAD binding sites in the promoter of COX-2. Cell line models exhibiting overexpression or knockdown of some genes were generated using transfection agents. Coimmunoprecipitation was used to detect protein mutual interaction. mRNA and protein levels were measured by qRT-PCR and western blot respectively. Here, we reported that both YAP and COX-2 were overexpressed in colorectal cancer cells. YAP increased COX-2 expression at the level of transcription requiring intact TEAD binding sites in the COX-2 promoter. YAP conferred drug resistance through COX-2 and its related effectors such as MCL, MDR, Survivin. GCCSysm-4 (G-4), a YAP and COX-2 inhibitor, effectively inhibited both YAP and COX-2 activation, induced apoptosis and decreased viability in Taxol-resistant cells. Inhibition of YAP and COX-2 acted synergistically and more efficiently reduced the resistance of CRC cells than either of them alone. Our data provide new mechanisms that YAP is a new upstream regulator of COX-2 pathway and plays an important role in conferring resistance in CRC cells. G-4, targeting YAP-COX-2, may be a novel valuable strategy to combat resistance in CRC.
- 16 October 2017
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 36 (1) , 1-20
Open AccessYAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer
Chemotherapy resistance remains a major challenge in cancer treatment. COX-2 (cyclooxygenase 2) is involved in drug resistance and poor prognosis of many neoplastic diseases or cancers. However, investigations identifying new modulators of COX-2 pathway and searching for new chemicals targeting these valid resistant biomarkers are still greatly needed. HCT15, HCT-116, HT-29, COLO205, FHC, IMCE, SW480 cell lines were used to detect the expression of YAP and COX-2. Site-directed mutagenesis, luciferase reporter analysis and ChIP assay were used to test whether YAP activated COX-2 transcription through interaction with TEAD binding sites in the promoter of COX-2. Cell line models exhibiting overexpression or knockdown of some genes were generated using transfection agents. Coimmunoprecipitation was used to detect protein mutual interaction. mRNA and protein levels were measured by qRT-PCR and western blot respectively. Here, we reported that both YAP and COX-2 were overexpressed in colorectal cancer cells. YAP increased COX-2 expression at the level of transcription requiring intact TEAD binding sites in the COX-2 promoter. YAP conferred drug resistance through COX-2 and its related effectors such as MCL, MDR, Survivin. GCCSysm-4 (G-4), a YAP and COX-2 inhibitor, effectively inhibited both YAP and COX-2 activation, induced apoptosis and decreased viability in Taxol-resistant cells. Inhibition of YAP and COX-2 acted synergistically and more efficiently reduced the resistance of CRC cells than either of them alone. Our data provide new mechanisms that YAP is a new upstream regulator of COX-2 pathway and plays an important role in conferring resistance in CRC cells. G-4, targeting YAP-COX-2, may be a novel valuable strategy to combat resistance in CRC.